DOAC-Stop™ 50 micro-tablets

DOAC-Stop™ is an adsorbent product that extracts Direct Oral Anticoagulants (DOACs) from plasmas in research settings. DOAC-Stop™ micro-tablets are just like DOAC-Stop™ mini-tablets but optimized for small sample sizes.

DOAC-Stop™ can be used in research studies to efficiently eliminate Direct Oral Anti-Coagulants, DOACs including dabigatran, apixaban, rivaroxaban and edoxaban, from test plasmas with minimal effect on plasma proteins involved in the clotting mechanism.

DOAC-Stop™ can be used in research studies to evaluate the presence of DOACs in subject plasma samples using simple clotting tests.

DOAC-Stop™ micro-tablets are stable for three (3) years when stored at 2-8°C.

DOAC-Stop™ can be used in research studies to efficiently eliminate Direct Oral Anti-Coagulants, (including dabigatran, apixaban, rivaroxaban and edoxaban), from test plasmas with minimal effect on plasma proteins involved in the clotting mechanism.

DOAC-Stop™ can be used in research studies to evaluate the presence of DOACs in subject plasma samples using simple clotting tests. DOAC-Stop™ is an adsorbent product that extracts DOACs from plasmas.

Limitations
DOAC-Stop™ may extract low molecular weight compounds resembling DOACs from plasmas. Those affecting coagulation (but administered intravenously, not orally) include argatroban, aprotinin, protamine, hirudin analogues, polymyxin and related cationic compounds.

Precautions
DOAC-Stop™ is intended for use with plasma samples suspected to contain DOACs in research settings. If test results are unchanged by DOAC-Stop™ and DOACs are still suspected to be present, apply appropriate chromogenic anti-Factor Xa or anti- Factor IIa assays to obtain specific DOAC results. Contact Diapharma for product info and technical support.

Store in a dry area at room temperature. Do not use after the expiry date indicated on the label. Treat all material as potentially infectious and dispose in accordance with local operating regulations. For further information, please refer to Safety Data Sheet and Product Information.

For Research Use Only in the US and Canada. Not for use in diagnostic procedures.

Background
DOACs are known to interfere with almost all clotting tests to varying degrees. Thus, in the coagulation research laboratory, plasmas giving unexpectedly prolonged clotting time or abnormal chromogenic test results may need to be screened for the presence of DOACs. Sometimes study subjects to be tested for underlying coagulation defects may also be on DOACs. DOAC-Stop™ is the first general agent available for solving the interference problems associated with DOACs. After treatment with DOAC-Stop™, plasma samples can be analyzed for factor deficiencies, heparin, lupus anticoagulant, or other interfering antibodies.

Just add one DOAC-Stop micro-tablet per 0.5mL citrated test plasma, mix until fully dispersed and then a further five minutes, and centrifuge down the particulate matter. The resulting supernatant plasma is then depleted of DOACs and yields similar APTT, dRVVT, PT(INR) and other results as if DOACs had not been present.

DOAC-Stop may be useful for identifying if DOACs are present and also for providing DOAC-free plasmas, enabling the analysis of a range of hemostatic parameters in test plasma. It leaves no residual effect. It can be used for checking if DOACs are present in samples giving unexpectedly prolonged clotting test or abnormal chromogenic test results.

There is negligible interference with vitamin K antagonist or heparinoid anticoagulants. Plasmas treated with DOAC-Stop™ can be used for valid factor assays in thrombosis research.